Plandai Biotechnology Inc. (OTC Markets: PLPL) (the “Company” or “Plandai”). Based on the results of published studies, the addition of generic green tea catechins to the diets of both broilers and layers has been shown to improve the productive performance and reduce the cholesterol content in the serum and egg yolk, implying its potential effect on egg-quality parameters. Furthermore, the addition of generic green tea catechins in the chickens’ diet decreases all microflora counts in the caecum due to an antibiotic-like effect.

In this review, it was found that green tea catechins’ inclusion in broiler diets had positive effects on growth performance and lean meat production, whereas catechins in high dosage tended to decrease feed intake and body weight gain but delivered an improved feed conversion ratio.

Cited  Khan, S.H., 2014, ‘The use of green tea (Camellia sinensis) as a phytogenic substance in poultry diets’, Onderstepoort Journal of Veterinary Research 81(1), Art. #706, 8 pages. https://dx.doi.org/10.4102/ojvr.v81i2.706

However, commercialization of generic green tea catechins as a phytogenic to the poultry industry has been restricted due to metabolization in the intestine and poor absorption.  In all prior studies and investigations, the catechin concentrations delivered to the target tissues in chickens were found to be too low to perform any effective antioxidant defense.

Plandai proprietary sciences have overcome the bioavailability challenges with Phytofare® catechin complex with independent clinical validation in both humans and poultry studies that have addressed the known pharmacokinetics barriers of isomeric form and identification: solubility, dosage, permeability, metabolism, excretion, target uptake and disposition.

Callum Cottrell-Duffield, COO, commented, “What previous independent published studies have demonstrated is that generic green tea catechins, when added to the diet of both egg layers and broilers, delivers improved gut maintenance, which ultimately translates to healthier and stronger chickens.   Once commercially proven and formulated as a phytogenic premix, the antioxidants should deliver a dramatic improved financial and wellness benefit to the poultry industry through increased production capacity and improved profit margins.”

About Plandai Biotechnology, Inc.

Plandai Biotechnology, Inc. (OTC Markets: PLPL) develops highly bioavailable, phytonutrient rich extracts which are being utilized to deliver a new family of drugs to safely and affordably treat a multitude of diseases and conditions. Plandai Biotechnology, through its South African subsidiaries, controls every aspect of production, from growing specific raw materials such as green tea on its farms to producing its proprietary Phytofare extract, allowing the Company to guarantee the continuity of supply as well as quality control throughout the entire process. The manufacturing facility has also been engineered for citrus fruits and the recovery of limonoids. Targeted industries for the Company’s products include animal health, dietary supplements, diabetes and cannabis. Plandai Biotechnology is headquartered in London, United Kingdom. For more information, please visit: https://www.plandaibiotech.com

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than statements of historical facts included in this press release are forward-looking statements. These statements relate to future events or to the Company’s future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Investors should not place any undue reliance on forward-looking statements since they involve known and unknown, uncertainties and other factors which are, in some cases, beyond the Company’s control which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company’s current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to operations, results of operations, growth strategy and liquidity. Such risks, uncertainties and other factors, which could impact the Company and the forward-looking statements contained herein are included in the Company’s filings with the OTC Markets. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.